Fig. 2From: Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancera Change from baseline in sum of longest diameters of target lesions (n = 21) and (b) change from baseline over time (n = 21)Back to article page